Filing Details
- Accession Number:
- 0001029142-25-000065
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-26 17:04:10
- Reporting Period:
- 2025-03-24
- Filing Date:
- 2025-03-26
- Accepted Time:
- 2025-03-26 17:04:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1029142 | Dynavax Technologies Corp | DVAX | Pharmaceutical Preparations (2834) | 330728374 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1573072 | F David Novack | C/O Dynavax Technologies 2100 Powell Street, Suite 720 Emeryville CA 94608 | President & Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-03-24 | 10,000 | $6.81 | 18,078 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-03-24 | 10,000 | $14.00 | 8,078 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-24 | 10,000 | $0.00 | 10,000 | $6.81 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
186,528 | 2026-12-15 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 6, 2024.
- This transaction was executed in two trades at $14.00. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
- This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of December 16, 2019, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
- Not applicable.